Abcuro

Abcuro is a clinical-stage biotechnology company developing first-in-class immunotherapies for autoimmune diseases and cancer by precisely modulating T cells and NK cells expressing KLRG1 (Killer Cell Lectin-Like Receptor G1). In certain autoimmune diseases, T cells expressing KLRG1 are a source of chronic tissue damage. In oncology, tumor cells expressing E- or N-cadherin suppress the anti-tumor activity of T cells and NK cells through their KLRG1 receptor, thus acting as an immune checkpoint inhibitory receptor. Through Abcuro's robust utilization of patient clinical data and patient tissue transcriptome analysis of discrete pathologic immune cell subsets, KLRG1 has been identified as a compelling target relevant to disease biology.